US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

38.98

+0.09480.24%

Volume:21.20K

Turnover:825.48K

Market Cap:355.46M

PE:- -

High:39.08

Open:38.96

Low:38.82

Close:38.88

52wk High:39.80

52wk Low:30.66

Shares:9.12M

Float Shares:9.12M

Volume Ratio:0.41

T/O Rate:0.23%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released

Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting

BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026

Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026

NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026

Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO

Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026

Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma

Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology

Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial

Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting

Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors

2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released

Imugene Reports 81% Overall Response Rate in Azer-Cel Phase 1b Study, Shares Surge 22%

MT Newswires Live

Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026

Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026

Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting

Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/stock/ORR/news?page=4"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":38.9763,"timestamp":1787683945856,"preClose":38.8815,"halted":0,"volume":21195,"delay":0,"changeRate":0.002438177539446763,"floatShares":9120000,"shares":9120000,"eps":0,"marketStatus":"Trading","change":0.0948,"latestTime":"08-25 14:57:40 EDT","open":38.96,"high":39.08,"low":38.82,"amount":825481.02915,"amplitude":0.006687,"askPrice":39.01,"askSize":100,"bidPrice":38.92,"bidSize":715,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1787688000000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":38.8815,"sharesOutstanding":12900000,"nav":38.62,"aum":352214400,"bidAskSpread":0,"preHourTrading":{"tag":"盘前","latestPrice":38.9089,"preClose":38.8815,"latestTime":"08:22 EDT","volume":2624,"amount":102252.0976,"timestamp":1787660560078,"change":0.0274,"changeRate":0.000705,"amplitude":0.001829},"postHourTrading":{"tag":"盘后","latestPrice":38.85,"preClose":38.8815,"latestTime":"19:30 EDT","volume":11,"amount":427.8905,"timestamp":1787614207188,"change":-0.0315,"changeRate":-0.00081,"amplitude":0},"volumeRatio":0.405821,"impliedVol":0.12,"impliedVolPercentile":0.4214},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9120000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.405821,"shares":9120000,"dividePrice":0,"high":39.08,"amplitude":0.006687,"preClose":38.8815,"low":38.82,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":38.9763,"committee":0.754601,"eps":0,"divideRate":0,"volume":21195,"delay":0,"ttmEps":0,"open":38.96,"prevYearClose":34.16,"prevWeekClose":38.69,"prevMonthClose":38.79,"prevQuarterClose":36.32,"fiveDayClose":37.76,"twentyDayClose":37.3537,"sixtyDayClose":35.88},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:20,pageCount:4,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2640978848","title":"ASCO 2026 | Updated Data from an Oral Presentation of InnoCare's Novel BCL2 Inhibitor Mesutoclax in MDS and AML Released","url":"https://stock-news.laohu8.com/highlight/detail?id=2640978848","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640978848?lang=en_us&edition=fundamental","pubTime":"2026-06-03 10:47","pubTimestamp":1780454820,"startTime":"0","endTime":"0","summary":"BEIJING, June  02, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced toda","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/03/3305756/0/en/ASCO-2026-Updated-Data-from-an-Oral-Presentation-of-InnoCare-s-Novel-BCL2-Inhibitor-Mesutoclax-in-MDS-and-AML-Released.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1093756325.SGD","LU1721428933.USD","BK4533","IE00BFXG0V08.USD","ORR","BK4585","BK4567","BK4161","IE00BYQQ9H92.USD","LU2211817866.USD","CR","IE00B5TLWC47.USD","LU0347712357.USD","BK4588","BK4121","BK4548","LU2413666699.HKD","MTD","LU1093756168.USD","LU2413666426.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640945316","title":"Cardiff Oncology Announces Presentation of Positive Results from its Randomized, Controlled Phase 2 Trial of Onvansertib in First-Line RAS-Mutated mCRC at the 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2640945316","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640945316?lang=en_us&edition=fundamental","pubTime":"2026-06-02 21:06","pubTimestamp":1780405560,"startTime":"0","endTime":"0","summary":"- The trial achieved its primary goal of selecting the efficacious and safe dose of onvansertib + standard-of-care (SoC) regimen for the registrational program - - 30 mg onvansertib + FOLFIRI/bevacizu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305287/0/en/Cardiff-Oncology-Announces-Presentation-of-Positive-Results-from-its-Randomized-Controlled-Phase-2-Trial-of-Onvansertib-in-First-Line-RAS-Mutated-mCRC-at-the-2026-ASCO-Annual-Meeti.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BZ199S13.USD","BK4141","IE00BFMHRM44.USD","BK4211","LU0124384867.USD","LU0348723411.USD","HR","LU1854104046.USD","BK4225","LU0054578231.USD","LU1720051017.SGD","LU1548497426.USD","LU1861220033.SGD","ORR","LU1854103824.USD","BK4203","LU1861214812.USD","LU1861219969.SGD","LU1978683503.SGD","ITT","IE00BD6J9T35.USD","BK4195","LU0053671581.USD","BK4605","LU1861215975.USD","LU0724618433.USD","LU2298322129.HKD","BK4161","LU1720051108.HKD","LU2357305700.SGD","BK4588","ON","BK4585","PFS","BK4512","LU2360107325.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640175949","title":"BeyondSpring Presents the Latest Update of a Phase 2 Study Demonstrating Durable Clinical Benefit of Pembrolizumab Plus Plinabulin/Docetaxel in Metastatic NSCLC After Progression on First-Line Immune Checkpoint Inhibitor Therapy at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640175949","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640175949?lang=en_us&edition=fundamental","pubTime":"2026-06-02 19:00","pubTimestamp":1780398000,"startTime":"0","endTime":"0","summary":"Meaningful clinical benefit: Median PFS at 7.0 months, median DoR is 9.3 months with DCR of 79.5% in metastatic NSCLC patients with acquired resistance to immune checkpoint inhibitorsDurable survival ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3304984/0/en/BeyondSpring-Presents-the-Latest-Update-of-a-Phase-2-Study-Demonstrating-Durable-Clinical-Benefit-of-Pembrolizumab-Plus-Plinabulin-Docetaxel-in-Metastatic-NSCLC-After-Progression-o.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BYSI","LU0053666078.USD","PFS","LU0210528500.USD","BK4195","BK4213","LU2487616109.SGD","ORR","BK4080","ADC","BK4139","BK4107","BK4585","BK4588","AR","L","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640570849","title":"Legend Biotech Presents First-in-Human LB2102 Results in Solid Tumors and New CARVYKTI® Data in Multiple Myeloma at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640570849","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640570849?lang=en_us&edition=fundamental","pubTime":"2026-06-01 22:00","pubTimestamp":1780322400,"startTime":"0","endTime":"0","summary":"LB2102 demonstrated a manageable safety profile and encouraging clinical activity in solid tumors among heavily pretreated patientsResponses observed at higher dose levels of LB2102 with an ORR of 28.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304508/0/en/Legend-Biotech-Presents-First-in-Human-LB2102-Results-in-Solid-Tumors-and-New-CARVYKTI-Data-in-Multiple-Myeloma-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1543694498.USD","LU1620156213.USD","CRS","MAS","BK4086","LU1596574779.USD","BK4505","LU1721427968.SGD","BK4588","LU2413665964.HKD","PML","IE00B19Z4B17.USD","LU0963586101.USD","LU1620156130.USD","LU2413666004.HKD","CAR","IE0031619046.USD","SG9999001440.SGD","EC","BK4201","LU0170899867.USD","BK4581","IE00B7SZL793.SGD","BK4585","LEGN","ORR","BK4006","IEC","BK4187","IE00B66KJ199.SGD","BK4230","LU2065731478.USD","LU1165135440.EUR","XBI","BK4022","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640951862","title":"NextCure Presents Positive SIM0505 Phase 1 Dose Escalation Data in Patients with Gynecologic Cancers at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640951862","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640951862?lang=en_us&edition=fundamental","pubTime":"2026-06-01 20:00","pubTimestamp":1780315200,"startTime":"0","endTime":"0","summary":"55% ORR in gynecologic cancers with 52.9% in ovarian and 66.7% in USC at 12 weeks by best response per RECIST 1.1 within the therapeutic dose range (4.8 – 8.0 mg/kg)Favorable safety and tolerability i","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304283/0/en/NextCure-Presents-Positive-SIM0505-Phase-1-Dose-Escalation-Data-in-Patients-with-Gynecologic-Cancers-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","ADC","BK4080","BK4007","PR","BK4213","ORR","PROC","RCC","KOL"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640804959","title":"Immuneering Presents Compelling 17.3-Month Median Overall Survival and Favorable Tolerability with Atebimetinib + Chemotherapy in First-Line Pancreatic Cancer Patients at ASCO","url":"https://stock-news.laohu8.com/highlight/detail?id=2640804959","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640804959?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:30","pubTimestamp":1780313400,"startTime":"0","endTime":"0","summary":"- 17.3 months median overall survival in 55 first-line pancreatic cancer patients; vs. 8.5 months for standard of care chemotherapy in the pivotal MPACT study - - Only two categories of Grade 3+ treat","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304230/0/en/Immuneering-Presents-Compelling-17-3-Month-Median-Overall-Survival-and-Favorable-Tolerability-with-Atebimetinib-Chemotherapy-in-First-Line-Pancreatic-Cancer-Patients-at-ASCO.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ORR","BK4539","BK4563","IMRX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640894409","title":"Ascentage Pharma Presents Its First Dataset on MDM2-p53 Inhibitor Alrizomadlin (APG-115) in Pediatric Solid Tumors at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640894409","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640894409?lang=en_us&edition=fundamental","pubTime":"2026-06-01 07:30","pubTimestamp":1780270200,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, May  31, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303965/0/en/Ascentage-Pharma-Presents-Its-First-Dataset-on-MDM2-p53-Inhibitor-Alrizomadlin-APG-115-in-Pediatric-Solid-Tumors-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CDE","BK4017","BK4139","AAPG","EWS","LU1223083913.SGD","LU2125909759.SGD","APG","LU1223082519.USD","BK4161","ORR","BK4129","LU1223082196.USD","LU2125909916.SGD","NB","LU1923622291.USD","BK4168","CR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639988566","title":"Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2639988566","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639988566?lang=en_us&edition=fundamental","pubTime":"2026-05-31 20:00","pubTimestamp":1780228800,"startTime":"0","endTime":"0","summary":"Immunocore presents updated Phase 1 data of brenetafusp in patients with heavily pretreated advanced melanoma Brenetafusp monotherapy resulted in a 6-month overall survival rate of 87% and disease con","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303917/0/en/Immunocore-presents-updated-Phase-1-data-of-brenetafusp-in-patients-with-heavily-pretreated-advanced-melanoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BYQQ9H92.USD","LU0053666078.USD","ORR","BK4207","BK4567","BK4195","IE00BFXG0V08.USD","LU1093756168.USD","LU2211817866.USD","LU2487616109.SGD","BK4533","BK4588","MTD","LU1721428933.USD","LU0347712357.USD","IE00B5TLWC47.USD","BK4107","PFS","LU2413666426.HKD","BK4585","BK4211","BK4548","L","LU2413666699.HKD","CM","BK4121","LU0210528500.USD","LU1093756325.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639569988","title":"Replimune Presents Final First-in-Human Data for RP2 in Advanced Solid Tumors During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2639569988","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639569988?lang=en_us&edition=fundamental","pubTime":"2026-05-31 20:00","pubTimestamp":1780228800,"startTime":"0","endTime":"0","summary":"WOBURN, Mass., May  31, 2026  (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today pres","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303918/0/en/Replimune-Presents-Final-First-in-Human-Data-for-RP2-in-Advanced-Solid-Tumors-During-Oral-Presentation-at-the-2026-American-Society-of-Clinical-Oncology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1815336091.USD","ORR","IE00B66KJ199.SGD","BK4139","IE00B19Z4B17.USD","AEIS","AFG","BK4157","LU0757428866.USD","MAGE","REPL","IE0031619046.USD","BK4117","BK4107","IE00B7SZL793.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639048566","title":"Eikon Therapeutics Presents Data on Clinical-Stage Programs at the 2026 Annual Meeting of the American Society of Clinical Oncology","url":"https://stock-news.laohu8.com/highlight/detail?id=2639048566","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639048566?lang=en_us&edition=fundamental","pubTime":"2026-05-31 02:30","pubTimestamp":1780165800,"startTime":"0","endTime":"0","summary":"TeLuRide-005, a Phase 2 trial of EIK1001 in first-line patients with stage 4 NSCLC completed enrollment of both non-squamous and squamous cohorts and reports updated rates of response and disease cont","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/30/3303899/0/en/Eikon-Therapeutics-Presents-Data-on-Clinical-Stage-Programs-at-the-2026-Annual-Meeting-of-the-American-Society-of-Clinical-Oncology.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["EIKN","ORR","LU2065731478.USD","LU0053666078.USD","IE0031619046.USD","LU0210528500.USD","LU0963586101.USD","LU2487616109.SGD","BK4588","BK4187","IE00B7SZL793.SGD","CRS","AFG","BK4006","BK4107","BK4139","IE00B66KJ199.SGD","BK4117","SSI","BK4585","IE00B19Z4B17.USD","L"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639601202","title":"Global Data for BioNTech and Bristol Myers Squibb’s PD-L1xVEGF-A Bispecific Pumitamig Shows Encouraging Efficacy in Patients with Non-Small Cell Lung Cancer in ROSETTA Lung-02 Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2639601202","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639601202?lang=en_us&edition=fundamental","pubTime":"2026-05-31 02:15","pubTimestamp":1780164900,"startTime":"0","endTime":"0","summary":"First investigational PD-(L)1xVEGF bispecific immunomodulator to present global datashowingencouraging efficacyin combination with chemotherapyinfirst-linenon-small cell lung canceracrossPD-L1expressi","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/30/3303897/0/en/Global-Data-for-BioNTech-and-Bristol-Myers-Squibb-s-PD-L1xVEGF-A-Bispecific-Pumitamig-Shows-Encouraging-Efficacy-in-Patients-with-Non-Small-Cell-Lung-Cancer-in-ROSETTA-Lung-02-Tria.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0225771236.USD","LU0114720955.EUR","LU1883839398.USD","BK4107","LU0985481810.HKD","IE00BFXG1179.USD","BK4023","ORR","LU1670711040.USD","BK4581","LU0321505439.SGD","BK4532","LU0267386448.USD","LU1868836914.USD","IE0002141913.USD","LU1868836591.USD","LU1261432733.SGD","IE00B2B36J28.USD","LU1093756168.USD","BK4534","IE00BFTCPJ56.SGD","LU0225284248.USD","LU0868494617.USD","IE00BJJMRZ35.SGD","LU2360032135.SGD","LU1093756325.SGD","BK4211","L","LU0321505868.SGD","PFS","LU1670710661.SGD","LU1989771016.USD","LU0210528500.USD","LU1430594728.SGD","BK4195","LU1868837300.USD","LU1868837136.USD","LU0882574055.USD","LU0096364046.USD","LU0306806265.USD","LU1868836757.USD","BMY","LU1571399168.USD","BMS","LU2242652126.USD","PD","BK4559","LU0061475181.USD","IE00BJT1NW94.SGD","IE00BSNM7G36.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639609563","title":"Replimune Presents 3-Year Landmark Overall Survival Analysis from IGNYTE Clinical Trial During Oral Presentation at the 2026 American Society of Clinical Oncology Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2639609563","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639609563?lang=en_us&edition=fundamental","pubTime":"2026-05-30 20:00","pubTimestamp":1780142400,"startTime":"0","endTime":"0","summary":"WOBURN, Mass., May  30, 2026  (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today pres","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/30/3303875/0/en/Replimune-Presents-3-Year-Landmark-Overall-Survival-Analysis-from-IGNYTE-Clinical-Trial-During-Oral-Presentation-at-the-2026-American-Society-of-Clinical-Oncology-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LARK","BK4139","BK4107","ORR","REPL","BK4117","AFG","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639095506","title":"Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2639095506","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2639095506?lang=en_us&edition=fundamental","pubTime":"2026-05-30 20:00","pubTimestamp":1780142400,"startTime":"0","endTime":"0","summary":"One-time infusion of IMA203CD8 PRAME cell therapy in the ongoing Phase 1 dose escalation/dose expansion trial achieved anti-tumor activity in platinum-resistant ovarian cancer and in uterine cancer wi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/30/3303876/0/en/Immatics-Presents-Clinical-Activity-of-IMA203CD8-PRAME-Cell-Therapy-in-Hard-to-Treat-Gynecologic-Cancers-at-2026-ASCO-Annual-Meeting.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMTX","IE0031619046.USD","LU0963586101.USD","IE00B66KJ199.SGD","CRS","IE00B7SZL793.SGD","BK4187","LU2065731478.USD","IE00B19Z4B17.USD","ORR","BK4139","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638513461","title":"Kura Oncology Reports Strong Clinical Activity and Safety with Darlifarnib + Adagrasib in KRAS G12C-Mutated Solid Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2638513461","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638513461?lang=en_us&edition=fundamental","pubTime":"2026-05-26 18:02","pubTimestamp":1779789720,"startTime":"0","endTime":"0","summary":"– Tumor shrinkage observed in 77% of response-evaluable patients, including in heavily pretreated and KRASi-experienced patients – – ORRs were 67% in PDAC, 50% in NSCLC, and 29% in KRASi-nave CRC pati","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3300885/35186/en/Kura-Oncology-Reports-Strong-Clinical-Activity-and-Safety-with-Darlifarnib-Adagrasib-in-KRAS-G12C-Mutated-Solid-Tumors.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CRC","BK4213","BK4179","LU0456854461.SGD","BK4139","FTI","LU2265009873.SGD","BK4505","LU2236285917.USD","LU0054578231.USD","LU2417539215.USD","LU0053671581.USD","IE00BD6J9T35.USD","KURA","ORR","LU0300736492.USD","LU1804176565.USD","LU2456880835.USD","LU0300736062.USD","LU0266512127.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637116373","title":"2026 ASCO | Pivotal Data of InnoCare's Novel BCL2 Inhibitor Mesutoclax Released","url":"https://stock-news.laohu8.com/highlight/detail?id=2637116373","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637116373?lang=en_us&edition=fundamental","pubTime":"2026-05-22 20:00","pubTimestamp":1779451200,"startTime":"0","endTime":"0","summary":"BEIJING, May  22, 2026  (GLOBE NEWSWIRE) -- InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3300080/0/en/2026-ASCO-Pivotal-Data-of-InnoCare-s-Novel-BCL2-Inhibitor-Mesutoclax-Released.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","ORR","IE00B64QTZ34.USD","PB","PFS","IE00BLDYK493.USD","TLS","BK4161","BK4097","BK4195","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637645073","title":"Imugene  Reports 81% Overall Response Rate in Azer-Cel Phase 1b Study, Shares Surge 22%","url":"https://stock-news.laohu8.com/highlight/detail?id=2637645073","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637645073?lang=en_us&edition=fundamental","pubTime":"2026-05-22 10:35","pubTimestamp":1779417331,"startTime":"0","endTime":"0","summary":"Imugene  said data from its azer-cel Phase 1b abstract, published on the American Society of Clinical Oncology  website, showed an overall response rate  of 81% among 16 evaluable patients, according to a Friday Australian bourse filing.The company said Azer-cel, an off-the-shelf allogeneic CAR T cell therapy targeting CD19 to treat blood cancers, showed responses across multiple lymphoma and leukemia subtypes, including a 60% response rate in diffuse large B-cell lymphoma  and a 100% response rate in marginal zone lymphoma .The company's shares rose 22% in recent Friday trade.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["ORR.AU","IMU.AU","ORR","BK7067","BK7508","BK7095"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637365900","title":"Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637365900","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637365900?lang=en_us&edition=fundamental","pubTime":"2026-05-22 08:00","pubTimestamp":1779408000,"startTime":"0","endTime":"0","summary":"ROCKVILLE, Md. and SUZHOU, China, May  21, 2026  (GLOBE NEWSWIRE) -- Ascentage Pharma Group International (NASDAQ: AAPG; HKEX: 6855), a global, commercial-stage, integrated biopharmaceutical company e","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3299861/0/en/Ascentage-Pharma-Releases-Latest-Clinical-Data-from-Multiple-Trials-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CR","BK4139","PD","BK4211","NB","AAPG","EWS","LU1169589451.USD","BK4161","LU1169590202.USD","BK4023","BK4168","ORR","PFS","BK4195"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357750","title":"Zentalis Pharmaceuticals to Present Phase 1b MUIR Trial Data Showing Encouraging Clinical Activity and Manageable Safety Profile of Azenosertib Plus Paclitaxel in Platinum-Resistant Ovarian Cancer at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357750","media":"GlobeNewswire","labels":["conferences","dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357750?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:39","pubTimestamp":1779399540,"startTime":"0","endTime":"0","summary":"In an all-comer PROC population, across multiple dose cohorts, manageable safety profile of the combination was observed with low frequency of high-grade adverse eventsActivity of the combined regimen","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299814/0/en/Zentalis-Pharmaceuticals-to-Present-Phase-1b-MUIR-Trial-Data-Showing-Encouraging-Clinical-Activity-and-Manageable-Safety-Profile-of-Azenosertib-Plus-Paclitaxel-in-Platinum-Resistan.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences,dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","ORR","PFS","BK4195","PROC","BK4211"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637357754","title":"Crescent Biopharma Announces Trial in Progress Presentation for ASCEND Study of CR-001, a PD-1 x VEGF Bispecific Antibody, at Upcoming American Society of Clinical Oncology (ASCO) 2026 Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2637357754","media":"GlobeNewswire","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637357754?lang=en_us&edition=fundamental","pubTime":"2026-05-22 05:30","pubTimestamp":1779399000,"startTime":"0","endTime":"0","summary":"ASCEND Phase 1/2 global clinical trial evaluating CR-001 in multiple solid tumor types, including NSCLC, gastrointestinal and gynecological cancers in first-line and previously treated patients Multip","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299810/0/en/Crescent-Biopharma-Announces-Trial-in-Progress-Presentation-for-ASCEND-Study-of-CR-001-a-PD-1-x-VEGF-Bispecific-Antibody-at-Upcoming-American-Society-of-Clinical-Oncology-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PRGS","BK4107","PFS","BK4023","BK4211","BK4195","ORR","BK4117","LU1169590202.USD","BK4097","AFG","LU2065732104.USD","PD","LU1169589451.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637211382","title":"Junshi Biosciences Announces Approval of Toripalimab NDA for the 1st-line treatment of HER2 Expressing Urothelial Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2637211382","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637211382?lang=en_us&edition=fundamental","pubTime":"2026-05-21 18:28","pubTimestamp":1779359280,"startTime":"0","endTime":"0","summary":"SHANGHAI, May  21, 2026  (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/21/3299131/0/en/Junshi-Biosciences-Announces-Approval-of-Toripalimab-NDA-for-the-1st-line-treatment-of-HER2-Expressing-Urothelial-Carcinoma.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["RCC","BK4006","BK4203","HCC","ORR","BK4225","HR"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":4,"totalSize":134,"code":"91000000","status":"200"}]}}